Safety‑Only Drug Approval

The authors argue the FDA should require proof of safety but not efficacy, returning to the pre‑1962 standard. They contend this would cut a decade off timelines, slash costs, spur competition, and expand treatments for rare diseases without compromising safety. — This challenges the core U.S. drug‑approval doctrine and reframes high drug prices as a regulatory design problem rather than a pricing failure.